ProCE Banner Activity

Antibody–Drug Conjugates in Breast Cancer: Answers to Your FAQs

Clinical Thought

Read expert answers to clinically relevant questions about the use of antibody–drug conjugates (ADCs) in breast cancer management, including the recommended use of atropine for early-onset diarrhea in patients treated with sacituzumab govitecan and the use of prophylactic preservative-free eye drops for ocular toxicity associated with datopotamab deruxtecan. 

Released: April 28, 2025

Expiration: April 27, 2026

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Clinical Care Options, LLC (CCO) and Practicing Clinicians Exchange (PCE)

ProCE Banner

Supporters

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange, LLC

ProCE Banner

Disclosure

Primary Author

Elizabeth Diaz, PA-C, has no relevant financial relationships to disclose.

Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo.

Kimberly Podsada, MSN, NP-C, CNS: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Novartis, Pfizer.